$28.14
0.07% today
Nasdaq, Sep 16, 08:49 pm CET
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Cassava Sciences, Inc. Stock price

$28.12
+4.23 17.71% 1M
+7.47 36.17% 6M
+5.61 24.92% YTD
+8.59 43.98% 1Y
-19.00 40.32% 3Y
+26.90 2,204.92% 5Y
+1.66 6.27% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
-0.13 0.46%
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Key metrics

Market capitalization $1.35b
Enterprise Value $1.14b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 7.14
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-137.80m
Free Cash Flow (TTM) Free Cash Flow $-86.31m
Cash position $207.29m
EPS (TTM) EPS $-1.40
P/E forward negative
Short interest 35.18%
Show more

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Cassava Sciences, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Cassava Sciences, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Cassava Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.36 1.36
7% 7%
-
-1.36 -1.36
7% 7%
-
- Selling and Administrative Expenses 61 61
440% 440%
-
- Research and Development Expense 74 74
12% 12%
-
-136 -136
41% 41%
-
- Depreciation and Amortization 1.36 1.36
7% 7%
-
EBIT (Operating Income) EBIT -138 -138
41% 41%
-
Net Profit -15 -15
83% 83%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cassava Sciences, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.
Neutral
MarketBeat
about one month ago
Cassava Sciences NASDAQ: SAVA has become a hot topic among traders and active market participants thanks to its recent surge in volatility, liquidity, and overall market performance. Over the past month, shares have climbed 133% and are now more than 190% above their 52-week low.
Positive
Seeking Alpha
about one month ago
Cassava Sciences, Inc. announced its Q2 earnings earlier today. Management says it hopes to share pivotal Phase 3 study data for Alzheimer's drug candidate simufilam in 2024. The CEO and Head of Research resigned from the company a few weeks ago — possibly related to an ongoing SEC investigation into Cassava.
More Cassava Sciences, Inc. News

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Richard Barry
Employees 29
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today